Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

fontolizumab

Known as: HUZAF, Immunoglobulin G1, Anti-(Human Interferon Gamma) (Human-Mouse Monoclonal Huzaf Gamma-1-Chain), Disulfide with Human-Mouse Monoclonal Huzaf Light Chain, Dimer 
A humanized monoclonal antibody directed against interferon-gamma (IFN-g) with immunomodulatory activity. Fontolizumab binds to and prevents the… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and…
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and… Expand
Review
2014
Review
2014
Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease.
  • A. Kaser
  • Best practice & research. Clinical…
  • 2014
    • Corpus ID: 3277888
The recent success of the anti-integrin antibody Vedolizumab can barely conceal the fact that the biologics armamentarium in… Expand
Highly Cited
2010
Highly Cited
2010
Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study
Background: The safety and efficacy of fontolizumab, a humanized anti‐interferon gamma antibody, was investigated in patients… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2008
2008
Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome.
Therapeutic antibodies against tumor necrosis factor (TNF) (infliximab) and IFNgamma (fontolizumab) have been developed to treat… Expand
Highly Cited
2006
Highly Cited
2006
Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease
Introduction: Interferon γ is a potent proinflammatory cytokine implicated in the inflammation of Crohn’s disease (CD). We… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2006
Highly Cited
2006
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to…
Introduction: This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon γ antibody, in patients… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Review
2006
Review
2006
Interfering with interferons in inflammatory bowel disease
Early experience of fontolizumab, a humanised anti-interferon γ antibody, in active Crohn’s disease has shown that the drug… Expand
  • figure 1
  • table 1
  • figure 2
Review
2005
Review
2005
Fontolizumab Protein Design Labs.
  • F. Dumont
  • Current opinion in investigational drugs
  • 2005
    • Corpus ID: 42324864
Protein Design Labs is developing fontolizumab, a humanized anti-interferon gamma monoclonal antibody, for the potential… Expand
Review
2005
Review
2005
Advances in therapeutic approaches to ulcerative colitis and crohn’s disease
  • S. Travis
  • Current gastroenterology reports
  • 2005
    • Corpus ID: 39353292
Advances (from 2004 to 2006) in the use of conventional agents include the molecular mechanisms of action, which have… Expand
Review
2004
Review
2004
How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
  • W. Sandborn
  • Reviews in gastroenterological disorders
  • 2004
    • Corpus ID: 25358869
The chimeric monoclonal antibody to tumor necrosis factor (TNF), infliximab, is an effective therapy for Crohn's disease. However… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE